Evidence map›Paper›PMID 42699281›Full record

ArticleiScience2026

Importin-8 silencing reduces Ataxin-3 aggregation and alleviates Machado-Joseph disease/spinocerebellar ataxia type 3.

Inês Morgado Martins, Anna Sergeevna Sowa, David Rufino-Ramos, Diana Duarte Lobo, Kevin Leandro, Ana Vasconcelos-Ferreira, Dina Pereira, Olaf Rieβ, Thorsten Schmidt, Luís Pereira de Almeida

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in iScience, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Inês Morgado MartinsCNC-Center for Neuroscience and Cell Biology, Coimbra, Portugal.
Anna Sergeevna SowaInstitute of Medical Genetics and Applied Genomics, Eberhard Karls Universität Tübingen, Tübingen, Germany.
David Rufino-RamosCNC-Center for Neuroscience and Cell Biology, Coimbra, Portugal.
Diana Duarte LoboCNC-Center for Neuroscience and Cell Biology, Coimbra, Portugal.
Kevin LeandroCNC-Center for Neuroscience and Cell Biology, Coimbra, Portugal.
Ana Vasconcelos-FerreiraCNC-Center for Neuroscience and Cell Biology, Coimbra, Portugal.
Dina PereiraCNC-Center for Neuroscience and Cell Biology, Coimbra, Portugal.
Olaf RieβInstitute of Medical Genetics and Applied Genomics, Eberhard Karls Universität Tübingen, Tübingen, Germany.
Thorsten SchmidtInstitute of Medical Genetics and Applied Genomics, Eberhard Karls Universität Tübingen, Tübingen, Germany.
Luís Pereira de AlmeidaCNC-Center for Neuroscience and Cell Biology, Coimbra, Portugal.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Machado-Joseph disease (MJD) is a polyglutamine neurodegenerative disorder characterized by the formation of neuronal intranuclear Ataxin-3 inclusions. The nucleocytoplasmic transport is known to be profoundly dysregulated from early stages of neurodegeneration, further aggravating its progressive nature. To understand the contribution of these proteins in MJD, we screened the effect of 34 transport proteins on Ataxin-3 aggregation. Importin-8 (

Indexed as

Argonaute-2Ataxin-3 aggregationImportin-8Machado-Joseph diseaseNF-kB/p65 translocationNucleocytoplasmic transport

Identifiers

PMID42699281
PMCPMC13544303

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.